Generics Firms Seek To Establish Better Conditions For Post-Approval Change Flexibility
Concerns raised around defining ICH Q12 “established conditions” for post-approval changes and potential role of prior knowledge for legacy products discussed in the context of generic drug applications; likely residual lack of harmonization explored.